Currently, there are 151.49M common shares owned by the public and among those 110.04M shares have been available to trade.
Insiders at the company have transacted a total of 14 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 12 of these insider trades were purchases, accounting for 54,417,047 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 40,873 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 6.15, down -0.91%. The company’s stock has a 5-day price change of -5.69% and 25.75% over the past three months. AMRX shares are trading -9.88% year to date (YTD), with the 12-month market performance up to 161.72% higher. It has a 12-month low price of $1.24 and touched a high of $6.30 over the same period. AMRX has an average intraday trading volume of 1.45 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.33%, -2.91%, and 31.92% respectively.
Institutional ownership of Amneal Pharmaceuticals Inc (NASDAQ: AMRX) shares accounts for 24.79% of the company’s 151.49M shares outstanding.
It has a market capitalization of $1.68B and a beta (3y monthly) value of 1.33. The stock’s trailing 12-month PE ratio is 86.41, while the earnings-per-share (ttm) stands at $0.06. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.76% over the week and 5.18% over the month.
Analysts forecast that Amneal Pharmaceuticals Inc (AMRX) will achieve an EPS of $0.09 for the current quarter, $0.11 for the next quarter and $0.6 for 2024. The lowest estimate earnings-per-share for the quarter is $0.07 while analysts give the company a high EPS estimate of $0.15. Comparatively, EPS for the current quarter was $0.23 a year ago. Earnings per share for the fiscal year are expected to decrease by -7.81%, and 9.75% over the next financial year.
Looking at the support for the AMRX, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on April 07, 2021, with the firm’s price target at $5. Goldman coverage for the Amneal Pharmaceuticals Inc (AMRX) stock in a research note released on March 08, 2021 offered a Buy rating with a price target of $6.50. Guggenheim was of a view on December 14, 2020 that the stock is Buy, while Barclays gave the stock Overweight rating on December 14, 2020, issuing a price target of $4.50- $6. Goldman on their part issued Sell rating on July 27, 2020.
